China approves Brii Biosciences' COVID-19 treatment

Brii Biosciences

08/12/2021 14:05

BEIJING, Dec 8 (Reuters) - China's medical products
regulator said on Wednesday it has approved the use of BRII
Biosciences'  2137.HK  neutrialising antibody cocktail for
COVID-19, the first treatment of its type against the disease
approved in the country.
    The medicine, a combination of BRII-196/BRII-198, was
approved to treat mild COVID-19 and the disease of "normal type"
with high risk of progressing to hospitalization or death in
adults and teenagers aged 12-17, the National Medical Products
Administration said in a statement.   

 (Reporting by Roxanne Liu and Ryan Woo; Editing by Jan Harvey)
 ((meg.shen@thomsonreuters.com; 852-39525805;))